Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Clinical trial NCT06006403 · COMPLETED
Trial details
- NCT number
- NCT06006403
- Sponsor
- Chongqing Precision Biotech Co., Ltd
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-28
- Primary completion
- 2025-09-25
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.